XOMA royalty-2c.png
XOMA to Present At the UBS Global Life Sciences Conference On September 22
September 16, 2008 16:35 ET | XOMA Corporation
BERKELEY, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today that Steven Engle, Chairman and Chief...
XOMA royalty-2c.png
New Programs Added in Antibody Collaboration Between XOMA and Takeda
September 15, 2008 16:35 ET | XOMA Corporation
BERKELEY, Calif., Sept. 15, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today the initiation of new therapeutic...
XOMA royalty-2c.png
Texas A&M University System and XOMA Sign Memorandum of Understanding
September 10, 2008 16:35 ET | XOMA Corporation
COLLEGE STATION, Texas and BERKELEY, Calif., Sept. 10, 2008 (GLOBE NEWSWIRE) -- The Texas A&M University System and XOMA, Ltd (Nasdaq:XOMA), a leader in the discovery and development of...
XOMA royalty-2c.png
XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical Trials
September 09, 2008 13:57 ET | XOMA Corporation
BERKELEY, Calif., Sept. 9, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that it was awarded a $65 million multiple year contract from the National Institute of Allergy and...
XOMA royalty-2c.png
XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells
September 08, 2008 05:00 ET | XOMA Corporation
ROME, Sept. 8, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced interim data from two Phase 1 clinical studies of XOMA 052, an antibody drug candidate with an ultra high binding affinity of...
XOMA royalty-2c.png
XOMA Reports Second Quarter 2008 Financial Results
August 07, 2008 16:02 ET | XOMA Corporation
BERKELEY, Calif., Aug. 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its results for the quarter ended June...
XOMA royalty-2c.png
XOMA to Announce Second Quarter 2008 Financial Results and Host Conference Call On Thursday, August 7
August 04, 2008 07:00 ET | XOMA Corporation
BERKELEY, Calif., Aug. 4, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the Company will host a conference call...
XOMA royalty-2c.png
XOMA Announces Departure of CFO
July 28, 2008 08:30 ET | XOMA Corporation
BERKELEY, Calif., July 28, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that J. David Boyle II, XOMA's Vice President of Finance and Chief Financial Officer, has resigned from the...
XOMA royalty-2c.png
XOMA Begins Phase 2a Clinical Trial to Evaluate XOMA 629 Topical Gel as a Treatment for the Common Skin Disease, Impetigo
July 24, 2008 16:41 ET | XOMA Corporation
BERKELEY, Calif., July 24, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced the start of its Phase 2a clinical...
XOMA royalty-2c.png
XOMA 052 Phase 1 Data to be Presented At European Association for the Study of Diabetes Annual Meeting
July 15, 2008 07:30 ET | XOMA Corporation
BERKELEY, Calif., July 15, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced that results from two ongoing Phase 1...